Search

Author/Creator Cohn, A L

1. 994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC). (1st October 2019)

Authors:
Makker, V; Taylor, M H; Aghajanian, C; Oaknin, A; Mier, J; Cohn, A L; Marin, M Romeo; Lorenzo, R Bratos; Brose, M S; DiSimone, C; Messing, M J; Stepan, D E; Dutcus, C E; Wu, J; Schmidt, E V; Orlowski, R J; Sachdev, P; Shumaker, R; Herraez, A Casado
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study. (18th October 2018)

Authors:
Yoshino, T; Portnoy, D C; Obermannová, R; Bodoky, G; Prausová, J; Garcia-Carbonero, R; Ciuleanu, T; García-Alfonso, P; Cohn, A L; Van Cutsem, E; Yamazaki, K; Lonardi, S; Muro, K; Kim, T W; Yamaguchi, K; Grothey, A; O'Connor, J; Taieb, J; Wijayawardana, S R; Hozak, R R
Journal:
Annals of oncology
Issue:
Volume 30:Number 1(2019)
Page Start:
124
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. (28th December 2019)

Authors:
Yoon, H H; Bendell, J C; Braiteh, F S; Firdaus, I; Philip, P A; Cohn, A L; Lewis, N; Anderson, D M; Arrowsmith, E; Schwartz, J D; Gao, L; Hsu, Y; Xu, Y; Ferry, D; Alberts, S R; Wainberg, Z A
Journal:
Annals of oncology
Issue:
Volume 30:Number 12(2019)
Page Start:
2016
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search